Analyst Price Target is $11.67
▲ +489.23% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Galecto in the last 3 months. The average price target is $11.67, with a high forecast of $16.00 and a low forecast of $6.00. The average price target represents a 489.23% upside from the last price of $1.98.
Current Consensus is
The current consensus among 3 investment analysts is to buy stock in Galecto. This Buy consensus rating has held steady for over two years.
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.